Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Pruritus ani and perianal dermatoses

Essential points for quick revision.

Saved on this device
!
Itching with a changing ulcer or mass

Persistent induration, ulceration, bleeding, an unexplained anal mass or a changing lesion in lichen sclerosus needs diagnostic reassessment.

Action: Arrange the appropriate urgent specialist or suspected cancer referral; do not defer evaluation while repeatedly suppressing the appearance with topical steroid.

Synopsis

Find the cause of perianal itching through skin and anorectal assessment, distinguish irritant disease from infection or suspicious lesions and use diagnosis-specific topical treatment with review.

  • Pruritus ani is a symptom: examine the perianal skin and relevant anorectal findings before choosing treatment.
  • Stool leakage, sweating, rubbing and over-cleansing can maintain an itch–scratch cycle; reduce irritants and aim for soft formed stool.
  • A persistent unexplained anal ulcer or mass needs a direct referral decision and must not be hidden by repeated empiric steroid courses.

Key red flags

An unexplained anal mass or ulceration can require suspected cancer referral without a preceding FIT result.

Painful spreading inflammation, purulent discharge or systemic illness suggests infection or a collection rather than simple itch.

Ivory-white atrophic skin, scarring or a changing focal lesion requires assessment for lichen sclerosus and its complications.

Investigation priorities

01
Skin microscopy culture and appropriate scrapingFirst step

Assess a suspected bacterial or fungal contribution before diagnosis-specific therapy.

Management branches

Worked caseRemove a demonstrated contact trigger

A 50-year-old woman has three months of itching and soreness despite using cleansing wipes and several creams.

  1. Examination shows eczematous perianal skin without an ulcer, fungal morphology, anal mass or features of lichen sclerosus. Stool is formed and there is no leakage. Appropriate skin samples do not identify infection. Specialist patch testing identifies a preservative present in her wipes, providing a relevant exposure-linked diagnosis of allergic contact dermatitis.
  2. She stops the implicated wipes and fragranced preparations, cleans gently with lukewarm water and pats dry. For the diagnosed noninfected dermatitis, she uses the selected hydrocortisone acetate 1% cream sparingly on external affected skin twice daily for an agreed seven-day course, with plain barrier care and a scheduled review. The prescription excludes mucosal application, ulcerated skin and ongoing infection, and she receives fabric-fire and worsening-skin advice.

Key medicines

Sovereign hydrocortisone acetate 1% creamFor a confirmed suitable noninfected perianal dermatitis in an adult, apply a small amount sparingly to affected external skin twice daily; the selected SmPC permits two or three applications daily. The worked case uses seven days followed by review and stopping if resolved. Do not apply inside the anal canal or use an occlusive dressing.Exclude hydrocortisone or excipient hypersensitivity. Do not use on bacterial, viral or fungal skin infection, ulcers or local infection; urticaria and rosacea are also excluded. Avoid use for psoriasis under this SmPC. Prolonged or extensive treatment and moist/flexural or damaged skin increase absorption, atrophy and systemic steroid risk. No specific renal/hepatic adjustment is provided; keep treatment limited and review vulnerable patients. Pregnancy safety is inadequately established, so obtain an individual benefit-risk decision; no neonatal problems are documented for nursing mothers. Stop and reassess worsening infection, marked irritation, rebound burning or visual disturbance. No known interactions are listed. Paraffin-contaminated clothing or dressings burn more readily: avoid smoking and naked flames.
Cooper clotrimazole 1% skin creamApply a thin even layer to the affected external skin two or three times daily and rub in gently. A half-centimetre strip covers roughly a hand-sized area. Treat candidal skin infection for at least two weeks and dermatophyte infection for at least one month; reassess a nonresponding or uncertain lesion.Exclude clotrimazole or excipient hypersensitivity; do not use to treat scalp or nail infection. Cetostearyl alcohol and benzyl alcohol can cause local irritation or contact allergy. Avoid eyes and oral use. The product has no separate age schedule and no specified renal/hepatic adjustment; use only the indicated cutaneous formulation. Pregnancy use requires physician or midwife supervision; use during lactation is permitted. Latex contraception may be damaged, so use alternative precautions during treatment and for at least five days afterwards. Keep contaminated fabrics away from cigarettes and flames, and stop for a significant allergic or irritant reaction.
Open full textbook Answer 2 questions
Sources and review status6 sources · checked 8 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 8 Sept 2026; clinical approval remains outstanding.

  • BAD pruritus ani patient guidancePruritus ani and perianal dermatoses: November 2022 version, stated review due November 2025; still hosted when read 8 September 2026. Used for established irritant and self-care scope, not described as a newly updated guideline.
  • PCDS pruritus ani clinical guidancePruritus ani and perianal dermatoses: Updated 28 May 2022; assessment, differential, investigation and management sections read 8 September 2026.
  • PCDS lichen sclerosus guidancePruritus ani and perianal dermatoses: Updated 16 March 2025; anogenital recognition, diagnostic uncertainty and suspicious-lesion follow-up scopes read 8 September 2026.
  • NICE NG12 suspected cancer recognition and referralPruritus ani and perianal dermatoses: Current colorectal and anal recommendations 1.3.1–1.3.6 read 8 September 2026; distinguish FIT triage from direct mass/ulcer referral.
  • Sovereign hydrocortisone acetate 1% cream SmPCPruritus ani and perianal dermatoses: PL06464/0698; text 21 May 2024, eMC10 April 2025; actual4.1–4.8. Selected for diagnosed dermatitis, not undifferentiated pruritus.
  • Clotrimazole 1% cream selected UK SmPCPruritus ani and perianal dermatoses: Cooper PL60682/0017; text August 2025; actual indication, dose, duration, safety and latex interaction sections read 8 September 2026.
Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom